Cover Image
市場調查報告書

生化學工業:產品平台分析

Seikagaku Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256133
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
生化學工業:產品平台分析 Seikagaku Corporation - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 29 Pages
簡介

生化學工業是醫療機具廠商,從事尤其是複合糖質相關的醫藥品與醫療機器的製造及銷售。該公司尚有包含以複合糖質為主要成分的玻尿酸關節功能改善劑等產品。

生化學工業的基本資料

生化學工業概要

  • 主要資訊
  • 企業資料

生化學工業:R&D概要

  • 主要的治療範圍

生化學工業:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

生化學工業:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

生化學工業:藥物簡介

  • condoliase
  • CF-101
  • hyaluronate sodium
  • SI-614
  • SI-613

生化學工業:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

生化學工業:最近的開發平台趨勢

生化學工業:暫停中的計劃

生化學工業:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07780CDB

Summary

Global Markets Direct's, 'Seikagaku Corporation - Product Pipeline Review - 2015', provides an overview of the Seikagaku Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Seikagaku Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Seikagaku Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Seikagaku Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Seikagaku Corporation's pipeline products

Reasons to buy

  • Evaluate Seikagaku Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Seikagaku Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Seikagaku Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Seikagaku Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seikagaku Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Seikagaku Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Seikagaku Corporation Snapshot
    • Seikagaku Corporation Overview
    • Key Information
    • Key Facts
  • Seikagaku Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Seikagaku Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Seikagaku Corporation - Pipeline Products Glance
    • Seikagaku Corporation - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Seikagaku Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Seikagaku Corporation - Drug Profiles
    • condoliase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hyaluronate sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cinhyaluronate sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SI-613
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Seikagaku Corporation - Pipeline Analysis
    • Seikagaku Corporation - Pipeline Products by Target
    • Seikagaku Corporation - Pipeline Products by Route of Administration
    • Seikagaku Corporation - Pipeline Products by Molecule Type
    • Seikagaku Corporation - Pipeline Products by Mechanism of Action
  • Seikagaku Corporation - Recent Pipeline Updates
  • Seikagaku Corporation - Dormant Projects
  • Seikagaku Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • piclidenoson
  • Seikagaku Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Seikagaku Corporation, Key Information
  • Seikagaku Corporation, Key Facts
  • Seikagaku Corporation - Pipeline by Indication, 2015
  • Seikagaku Corporation - Pipeline by Stage of Development, 2015
  • Seikagaku Corporation - Monotherapy Products in Pipeline, 2015
  • Seikagaku Corporation - Pre-Registration, 2015
  • Seikagaku Corporation - Phase III, 2015
  • Seikagaku Corporation - Phase II, 2015
  • Seikagaku Corporation - Pipeline by Target, 2015
  • Seikagaku Corporation - Pipeline by Route of Administration, 2015
  • Seikagaku Corporation - Pipeline by Molecule Type, 2015
  • Seikagaku Corporation - Pipeline Products by Mechanism of Action, 2015
  • Seikagaku Corporation - Recent Pipeline Updates, 2015
  • Seikagaku Corporation - Dormant Developmental Projects,2015
  • Seikagaku Corporation - Discontinued Pipeline Products, 2015
  • Seikagaku Corporation, Other Locations
  • Seikagaku Corporation, Subsidiaries

List of Figures

  • Seikagaku Corporation - Pipeline by Top 10 Indication, 2015
  • Seikagaku Corporation - Pipeline by Stage of Development, 2015
  • Seikagaku Corporation - Monotherapy Products in Pipeline, 2015
  • Seikagaku Corporation - Pipeline by Top 10 Target, 2015
  • Seikagaku Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Seikagaku Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Seikagaku Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top